EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Carbonic Anhydrase 12 as a Novel Prognostic Biomarker and Therapeutic Target for High‐Risk Follicular Thyroid Carcinoma

Masashi Tanida iD, Tsuyoshi Takashima, Shinichiro Tahara iD, Masaharu Kohara, Haruka Kanai, Masami Suzuki, Motoyuki Suzuki, Mitsuyoshi Hirokawa, Ayana Suzuki, Shinya Sato, Daisuke Okuzaki, Satoshi Nojima iD und 3 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Masashi Tanida und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Graduate School of Medicine, The University of Osaka, Osaka, Japan. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Biomarkers, Tumor, Adenocarcinoma, Follicular, Carbonic Anhydrases. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS KAKENHI, AMED, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular thyroid carcinoma is generally associated with a favorable prognosis; however, a subset of follicular thyroid carcinoma shows poor prognosis and frequent distant metastases, and this subset is referred to as high‐risk follicular thyroid carcinoma. Difficulty in distinguishing high‐risk from low‐risk follicular thyroid carcinoma based on current diagnostic approaches leads to the overtreatment of patients with indolent disease. Therefore, the identification of novel biomarkers capable of reliably distinguishing high‐risk follicular thyroid carcinoma is essential for accurate risk stratification. Such biomarkers may serve as therapeutic targets for metastatic follicular thyroid carcinoma. This study aimed to identify novel prognostic markers and therapeutic targets for high‐risk follicular thyroid carcinoma. In this study, we conducted bulk ribonucleic acid sequencing of high‐risk follicular thyroid carcinoma, including widely invasive subtypes and metastatic tumors, and we identified carbonic anhydrase 12 as a candidate biomarker. Immunohistochemical analysis revealed significantly higher carbonic anhydrase 12 expression in follicular thyroid carcinoma than in benign follicular adenomas, particularly in widely invasive and encapsulated angioinvasive subtypes. High carbonic anhydrase 12 expression was an independent predictor of poor disease‐free survival, surpassing conventional clinicopathological parameters. Functional assays showed that carbonic anhydrase 12 promoted follicular thyroid carcinoma proliferation, invasion, and migration partly by regulating matrix metalloproteinase 2 expression. Furthermore, carbonic anhydrase 12 inhibitor U104 suppressed follicular thyroid carcinoma cell growth in a dose‐dependent manner, and its combination with lenvatinib exerted synergistic antiproliferative effects. Collectively, these findings identified carbonic anhydrase 12 as a novel prognostic biomarker of follicular thyroid carcinoma and a promising therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsBiomarkers, TumorAdenocarcinoma, FollicularCarbonic AnhydrasesHumansPrognosisFemaleMaleMiddle AgedCell ProliferationCell Line, TumorPhenylurea CompoundsAdultCell MovementQuinolinesAgedMatrix Metalloproteinase 2Gene Expression Regulation, NeoplasticDisease-Free Survival

Stichwörter der Autor:innen

biomarkerscarbonic anhydrase 12follicular thyroid carcinomalenvatinibmatrix metalloproteinase 2

Substanzen

Biomarkers, TumorPhenylurea CompoundslenvatinibQuinolinesCarbonic AnhydrasesMatrix Metalloproteinase 2

Autor:innen und Institutionen

  • Department of Pathology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
  • Department of Diagnostic Pathology and Cytology, Kuma Hospital, Kobe, Japan.
  • Department of Surgery, Yamashita Thyroid Hospital, Fukuoka, Japan.
  • Single Cell Genomics, Human Immunology, WPI Immunology Frontier Research Center, The University of Osaka, Osaka, Japan.

ORCID-Profile: Masashi Tanida, Shinichiro Tahara, Satoshi Nojima, Hidenori Inohara

Förderung

  • JSPS KAKENHI
  • AMED
  • Japan Agency for Medical Research and Development

Zitieren

APA

Tanida, M., Takashima, T., Tahara, S., Kohara, M., Kanai, H., Suzuki, M., Suzuki, M., Hirokawa, M., Suzuki, A., Sato, S., Okuzaki, D., Nojima, S., Matsui, T., Inohara, H., & Morii, E. (2026). Carbonic Anhydrase 12 as a Novel Prognostic Biomarker and Therapeutic Target for High‐Risk Follicular Thyroid Carcinoma. Cancer Science. https://doi.org/10.1111/cas.70248

Vancouver

Tanida M, Takashima T, Tahara S, Kohara M, Kanai H, Suzuki M, et al. Carbonic Anhydrase 12 as a Novel Prognostic Biomarker and Therapeutic Target for High‐Risk Follicular Thyroid Carcinoma. Cancer Science. 2026. doi:10.1111/cas.70248

BibTeX
@article{Tanida2026,
  author = {Tanida, Masashi and Takashima, Tsuyoshi and Tahara, Shinichiro and Kohara, Masaharu and Kanai, Haruka and Suzuki, Masami and Suzuki, Motoyuki and Hirokawa, Mitsuyoshi and Suzuki, Ayana and Sato, Shinya and Okuzaki, Daisuke and Nojima, Satoshi and Matsui, Takahiro and Inohara, Hidenori and Morii, Eiichi},
  title = {Carbonic Anhydrase 12 as a Novel Prognostic Biomarker and Therapeutic Target for High‐Risk Follicular Thyroid Carcinoma},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70248}
}
Kostenlos starten →